ElmediX

About ElmediX

ElmediX is a company focused on extending and improving the lives of cancer patients worldwide through innovative thermal therapy, a form of hyperthermia treatment. Founded in 2015 as a spin-off from the University of Antwerp, ElmediX aims to develop disruptive solutions for pancreatic cancer and other life-threatening diseases.

Products & Services

Thermal Therapy (Hyperthermia Treatment):An innovative cancer treatment developed by ElmediX with high effectiveness and without significant side effects (toxicity). It aims to improve the lifespan and quality of life for cancer patients.

Specialties

Thermal Therapy Hyperthermia Treatment Cancer Treatment Pancreatic Cancer Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 5400000 MR: - FA: up to 5 million euros FAN: 5400000	D: 2024-06-14 FD: 2024-06-14	-

Series A Latest

2024-06-14

$5.4M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John-Paul Bogers

Chief Executive Officer

J

Johan Van den Bossche

Chairman of the Board and Co-founder

G

Gaëlle Boulet

Chief Scientific Officer

L

Luigi Brancato

Chief Technical Officer

C

Carine Eliaerts

Chief Financial Officer

O

Oleg Rudenko

Chief Medical Officer

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

ElmediX Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised